03:49 AM EDT, 09/09/2024 (MT Newswires) -- Longboard Pharmaceuticals ( LBPH ) reported Sunday "positive" interim results from its study of bexicaserin as a potential treatment for developmental and epileptic encephalopathies.

The ongoing 52-week study of 52 participants aged 12 years old to 65 years old showed decreases of 57.3% to 58.2% in seizures over nine months of treatment, the life sciences firm said.

There were also continued favorable safety and tolerability results observed in the study, with the most common treatment-emergent adverse event being upper respiratory tract infections, COVID-19, pneumonia, sinusitis, decreased appetite, pyrexia and weight decrease.

Price: 34.87, Change: +0.01, Percent Change: +0.03